Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM NASDAQ:GNFT NASDAQ:MOR NYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.85+1.5%$0.89$0.65▼$4.47$5.38M0.348,794 shs3,696 shsGNFTGENFIT$4.85$4.47$3.41▼$4.93$242.62M1.097,393 shsN/AMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AMRKMerck & Co., Inc.$121.43+4.8%$115.79$75.40▼$125.14$300.13B0.1810.83 million shs7.36 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+2.91%-1.36%-6.24%+5.50%-7.43%GNFTGENFIT0.00%0.00%0.00%0.00%+11.24%MORMorphoSys0.00%0.00%0.00%0.00%0.00%MRKMerck & Co., Inc.+2.52%+2.34%+2.87%-5.07%+50.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.85+1.5%$0.89$0.65▼$4.47$5.38M0.348,794 shs3,696 shsGNFTGENFIT$4.85$4.47$3.41▼$4.93$242.62M1.097,393 shsN/AMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/AMRKMerck & Co., Inc.$121.43+4.8%$115.79$75.40▼$125.14$300.13B0.1810.83 million shs7.36 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+2.91%-1.36%-6.24%+5.50%-7.43%GNFTGENFIT0.00%0.00%0.00%0.00%+11.24%MORMorphoSys0.00%0.00%0.00%0.00%0.00%MRKMerck & Co., Inc.+2.52%+2.34%+2.87%-5.07%+50.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 1.00SellN/AN/AGNFTGENFIT 2.00Hold$7.0044.33% UpsideMORMorphoSys 0.00N/AN/AN/AMRKMerck & Co., Inc. 2.68Moderate Buy$128.185.56% UpsideCurrent Analyst Ratings BreakdownLatest MRK, MOR, APM, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026APMAptorum Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/6/2026APMAptorum Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/6/2026MRKMerck & Co., Inc. CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$125.005/1/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/1/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$150.00 ➝ $145.004/13/2026MRKMerck & Co., Inc. UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$130.00 ➝ $145.004/6/2026MRKMerck & Co., Inc. JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$125.00 ➝ $135.003/30/2026MRKMerck & Co., Inc. Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$142.003/20/2026MRKMerck & Co., Inc. CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$120.00 ➝ $125.003/17/2026MRKMerck & Co., Inc. Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K12.51N/AN/A$2.17 per share0.39GNFTGENFIT$41.52M5.84$0.07 per share69.34$1.50 per share3.23MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17MRKMerck & Co., Inc.$65.01B4.61$12.28 per share9.89$18.60 per share6.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$1.36MN/AN/AN/AN/AN/AN/AN/AN/AGNFTGENFIT$1.63MN/AN/AN/AN/AN/AN/AN/AN/AMORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/AMRKMerck & Co., Inc.$18.25B$3.5534.2312.422.5413.59%27.55%10.73%8/4/2026 (Estimated)Latest MRK, MOR, APM, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.402.80%+5.75%95.77%14 YearsCompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.780.78GNFTGENFIT0.093.743.74MORMorphoSys4.981.381.38MRKMerck & Co., Inc.1.021.301.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%GNFTGENFIT2.24%MORMorphoSys18.38%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%GNFTGENFIT4.20%MORMorphoSys0.05%MRKMerck & Co., Inc.0.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group306.35 million2.29 millionNot OptionableGNFTGENFIT12050.03 million47.92 millionNot OptionableMORMorphoSys730150.62 million150.55 millionNot OptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableMRK, MOR, APM, and GNFT HeadlinesRecent News About These CompaniesMerck Stock Gains On Positive EU Opinion For Cancer Therapy55 minutes ago | finance.yahoo.comAbbVie, Merck, Astra among winners of EU drug recommendations this week55 minutes ago | seekingalpha.comSummit downgraded at HC Wainwright after Merck data for sac-TMT55 minutes ago | msn.comMerck and Kelun's lung cancer combo bests Keytruda in late-stage trial55 minutes ago | seekingalpha.comStock Market Today: Dow Holds Gain Despite Consumer Data Surprise; Dell Soars On This News (Live Coverage)55 minutes ago | finance.yahoo.comWill Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?1 hour ago | zacks.comPharma Stock Pops On European Seal of Approval2 hours ago | schaeffersresearch.comMerck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.2 hours ago | barrons.comMerck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer3 hours ago | investors.comAmylyx Stock: Why the Full Pipeline Story Matters (MRK)...May 22 at 7:55 AM | marketbeat.comMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder CancerMay 22 at 7:55 AM | businesswire.comKeudell Morrison Wealth Management Invests $1.33 Million in Merck & Co., Inc. $MRKMay 22 at 7:13 AM | marketbeat.comMerck & Co., Inc. $MRK Shares Bought by Pinnbrook Capital Management LPMay 22 at 6:34 AM | marketbeat.comAxxcess Wealth Management LLC Buys 263,633 Shares of Merck & Co., Inc. $MRKMay 22 at 3:21 AM | marketbeat.com2 Reasons to Watch MRK and 1 to Stay CautiousMay 22 at 1:22 AM | finance.yahoo.comIngenia Therapeutics, a Clinical-Stage Biotechnology Company, Has Received Approval for an Initial Public Offering on the Korea Exchange (KRX)May 21 at 8:21 PM | finance.yahoo.comKelun, Merck's lung cancer combo improves survival in late-stage China trialMay 21 at 5:06 PM | reuters.comModerna, Merck cancer combo cuts melanoma spread risk at five yearsMay 21 at 5:03 PM | reuters.comEli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?May 21 at 11:16 AM | zacks.comTop Dividend Stocks To Consider In May 2026May 21 at 9:20 AM | finance.yahoo.comHow Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value OutlookMay 21 at 9:20 AM | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Pipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000By Jeffrey Neal Johnson | May 12, 20262 Stocks to Watch as the Quantum Space Gets More CrowdedBy Nathan Reiff | May 3, 2026Homebuilder Earnings: D.R. Horton Sticks Out as Pulte & NVR Sales TankBy Leo Miller | April 27, 2026MRK, MOR, APM, and GNFT Company DescriptionsAptorum Group NASDAQ:APM$0.85 +0.01 (+1.50%) As of 01:10 PM Eastern This is a fair market value price provided by Massive. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.GENFIT NASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 05/20/2026MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Merck & Co., Inc. NYSE:MRK$121.43 +5.55 (+4.79%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Lowe's Finds Support at $215 After Q1 Earnings Sell-Off Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
